APA Цитирование

Barlas, S. (2015). FDA Considers More Rigorous Enforcement For Homeopathic Products Over Safety Risks: New Labeling Is Possible; Pre-Market Testing Seems Unlikely. P T.

Chicago-стиль цитирования

Barlas, Stephen. "FDA Considers More Rigorous Enforcement For Homeopathic Products Over Safety Risks: New Labeling Is Possible; Pre-Market Testing Seems Unlikely." P T 2015.

MLA-цитирование

Barlas, Stephen. "FDA Considers More Rigorous Enforcement For Homeopathic Products Over Safety Risks: New Labeling Is Possible; Pre-Market Testing Seems Unlikely." P T 2015.

Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.